



August 15, 2016

Stephen W. Linton
Chairman
Eugene Bell Foundation

Dear Dr. Linton:

This letter is to confirm that the Eugene Bell Foundation (EBF) is one of the implementing partners of the endTB project, funded by UNITAID. The endTB project aims to radically change the treatment of drug-resistant tuberculosis by introducing new drugs and regimens to 2600 patients in 15 different countries.

One of our most important countries is the Democratic People's Republic of Korea (DPRK), where EBF has been active for over a decade. EBF has been working to expand access to diagnosis and treatment since 2008, and currently supports thousands of drug-resistant tuberculosis patients during this difficult treatment.

Over the course of the project, EBF is expected to support 150 North Korean patients in treatment with the new tuberculosis drugs, bedaquiline and delamanid. In addition, data on adverse events and outcome will be combined with patient cohorts from other countries, creating a large dataset that will inform the use of these drugs worldwide.

We are happy to continue our longstanding partnership with EBF into this new and exciting project. Please do not hesitate to contact me if you have any concerns or problems.

At your service,

A handwritten signature in black ink that reads "Alissa K. Scharf". The signature is fluid and cursive, with the first name "Alissa" and last name "Scharf" clearly legible.

Alissa K. Scharf, MPH
endTB Project Manager